ANTI-CRM 1
|
|
- $282 - $607
- Product name: ANTI-CRM 1
- CAS:
- MF:
- MW: 0
- EINECS:
- MDL Number:MFCD03454995
- Synonyms:Anti-XPO1 antibody produced in rabbit;ANTI-CRM 1;ANTI-EXPORTIN-1;Anti-emb;Anti-Exportin 1 (CRM1 homolog, yeast);Anti-DKFZp686B1823
3 prices
Selected condition：
Brand
- Sigma-Aldrich
Package
- 25μL
- 100μL
- ManufacturerSigma-Aldrich
- Product numberHPA042933
- Product descriptionAnti-XPO1 antibody produced in rabbit Prestige Antibodies? Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
- Packaging25μL
- Price$282
- Updated2023-06-20
- Buy
- ManufacturerSigma-Aldrich
- Product numberAV40465
- Product descriptionAnti-XPO1 antibody produced in rabbit affinity isolated antibody
- Packaging100μL
- Price$580
- Updated2026-04-30
- Buy
- ManufacturerSigma-Aldrich
- Product numberHPA042933
- Product descriptionAnti-XPO1 antibody produced in rabbit Prestige Antibodies? Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
- Packaging100μL
- Price$607
- Updated2026-04-30
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Sigma-Aldrich | HPA042933 | Anti-XPO1 antibody produced in rabbit Prestige Antibodies? Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution | 25μL | $282 | 2023-06-20 | Buy |
| Sigma-Aldrich | AV40465 | Anti-XPO1 antibody produced in rabbit affinity isolated antibody | 100μL | $580 | 2026-04-30 | Buy |
| Sigma-Aldrich | HPA042933 | Anti-XPO1 antibody produced in rabbit Prestige Antibodies? Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution | 100μL | $607 | 2026-04-30 | Buy |
Properties
storage temp. :-20°C
form :buffered aqueous glycerol solution
biological source :rabbit
form :buffered aqueous glycerol solution
biological source :rabbit
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|